E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Parapneumonic pleural effusion |
pleural effusion parapneumonique |
|
E.1.1.1 | Medical condition in easily understood language |
pleural effusion |
pleural effusion |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10071699 |
E.1.2 | Term | Infectious pleural effusion |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014569 |
E.1.2 | Term | Empyema drainage |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Comparison of the efficacy, in terms of drainge duration, of pleural drainage by Video-Assisted Thoracoscopic with pleural drainage by percutaneous drain associated with urokinase in the treatment of parapneumonic pleural effusion in children
|
Comparer l’efficacité, en terme de durée de drainage, du drainage pleural par thoracoscopie vidéo-assistée au drainage pleural par drain percutané associé à l’urokinase dans la prise en charge de l’épanchement pleural parapneumonique chez l’enfant |
|
E.2.2 | Secondary objectives of the trial |
Compare the two techniques in terms of efficacy, safety, tolerance and cost-effectiveness |
Comparer des deux techniques en termes d’efficacité, d'innocuité, de tolérance et de rapport coût-efficacité |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Eligible ages : 1 year to 15 years
- Eligible genders : both
- pleural fluid depth of at least 15mm, confirmed by ultrasound
- At least one of the following severity criteria :
1) fever continuing 48h after starting correct antibiotherapy
2) respiratory distress
3) mediastinal shift on the chest X-ray |
- Garçon ou fille âgé entre 1 et 15 ans
- Pneumonie avec épanchement pleural drainable confirmé par échographie thoracique (lame liquidienne > 15 mm)
- Au moins un critère de gravité suivant :
1) persistance de pyrexie 48 heures après le début d’une antibiothérapie bien conduite
2) détresse respiratoire
3) refoulement du médiastin à la radiographie de thorax
|
|
E.4 | Principal exclusion criteria |
- previous drainage by either Video-Assisted Thoracoscopic or pleural drainage by percutaneous drain with or without fribrinolytic
- congenital pulmonary disorders with lung function impairment
- chronic pulmonary disease associated with lung function impairment
- hemodynamic instability
- acquired immune deficiency
- secondary immune deficiency induced
- coagulopathy disorder (contraindication of thrombolytic therapy)
- pregnancy or breastfeeding patient |
- Drainage préalable par drain percutané ou chirurgical
- Affection congénitale pulmonaire ou altérant directement ou indirectement la fonction pulmonaire
- Affection pulmonaire chronique altérant la fonction pulmonaire
- Choc avec instabilité hémodynamique
- Immunodéficience congénitale ou acquise maligne ou médicamenteuse
- Anomalie de la coagulation contre-indiquant l’usage de fibrinolytiques
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Duration of drainage, in days |
Durée de drainage, en jours |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
End of drainage is defined as a drainage of < 1ml/kg/24h |
Fin du drainage définie comme un drain ramenant < 1 ml/kg/24h |
|
E.5.2 | Secondary end point(s) |
- Mortality rate
- Length of hospital stay
- Duration of oxygen therapy
- Duration of intravenous antibiotic therapy
- Duration of fever > 38.5°C after the initiation of therapy
- Patient disconfort
- serious and non-serious adverse event related to the therapy
- Inflammatory markers measurement
- Cost-effectiveness |
- taux de mortalité
- Durée d’hospitalisation totale
- Durée d’oxygéno-dépendance
- Durée d’antibiothérapie intraveineuse
- Durée de pyrexie (> 38.5°C après intervention)
- Inconfort du patient
- Complications associés à la technique de drainage
- Marqueurs inflammatoires sanguins
- Coût total de l’hospitalisation relative à l’épanchement pleural
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Evaluation of coagulation parameters at 48H post therapy initiation and at the drain removal (safety)
- Serious and non serious adverse events recorded throughout the patient hospital stay (safety)
- Safety visit performed 3 months after patient hospital discharged.
- Duration in terms of days for (length of hospital stay, duration of oxygen therapy, duration of intravenous antibiotic therapy, duration of fever > 38.5°C after therapy initiation (efficacy)
- Evaluation of leucocyte, neutrophile count, and CRP at 48H post therapy initiation and at the drain removal (efficacy)
- Post-therapy initiation analgesic consumption until patient hospital discharge (tolerability) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Pleural Drainage by Video-Assisted Thoracoscopic |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |